Trials / Terminated
TerminatedNCT02683148
DHEA in Synovial Sarcoma Patients
A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring G6PD inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DHEA | |
| OTHER | FACT-67 validated survey | * Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2 * 7 questions with answers ranging from 0=Not At All to 4 = Very Much. |
Timeline
- Start date
- 2016-09-13
- Primary completion
- 2018-09-09
- Completion
- 2019-04-04
- First posted
- 2016-02-17
- Last updated
- 2019-09-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02683148. Inclusion in this directory is not an endorsement.